Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
NEWS
                 Web Page URLs for STN Seminar Schedule - N. America
                 "Ask CAS" for self-help around the clock
NEWS
      2
NEWS
         Feb 24
                 PCTGEN now available on STN
NEWS
     4 Feb 24
                TEMA now available on STN
     5 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS
NEWS
     6 Feb 26 PCTFULL now contains images
      7 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS
NEWS
     8 Mar 24
                 PATDPAFULL now available on STN
NEWS
     9 Mar 24
                 Additional information for trade-named substances without
                 structures available in REGISTRY
NEWS 10
                 Display formats in DGENE enhanced
         Apr 11
         Apr 14
                 MEDLINE Reload
NEWS 11
NEWS 12
         Apr 17
                 Polymer searching in REGISTRY enhanced
                 Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 13
         Jun 13
NEWS 14
                 New current-awareness alert (SDI) frequency in
         Apr 21
                 WPIDS/WPINDEX/WPIX
NEWS 15
         Apr 28
                 RDISCLOSURE now available on STN
                 Pharmacokinetic information and systematic chemical names
NEWS 16
         May 05
                 added to PHAR
         May 15
                 MEDLINE file segment of TOXCENTER reloaded
NEWS 17
         May 15
                 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 18
NEWS 19
         May 19
                 Simultaneous left and right truncation added to WSCA
NEWS 20
         May 19
                 RAPRA enhanced with new search field, simultaneous left and
                 right truncation
NEWS 21
         Jun 06
                 Simultaneous left and right truncation added to CBNB
NEWS 22
         Jun 06
                 PASCAL enhanced with additional data
NEWS 23
                 2003 edition of the FSTA Thesaurus is now available
         Jun 20
NEWS 24
         Jun 25
                 HSDB has been reloaded
                 Data from 1960-1976 added to RDISCLOSURE
NEWS 25
         Jul 16
NEWS 26
         Jul 21
                 Identification of STN records implemented
NEWS 27
                 Polymer class term count added to REGISTRY
         Jul 21
         Jul 22
                 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and
NEWS 28
                 Right Truncation available
              April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
NEWS EXPRESS
              MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
              AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS INTER
              General Internet Information
NEWS LOGIN
              Welcome Banner and News Items
NEWS PHONE
              Direct Dial and Telecommunication Network Access to STN
NEWS WWW
              CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:28:02 ON 24 JUL 2003

=> file medline, uspatful, dgene, embase, scisearch, fsta, jicst, wpids, biosis,

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL SESSION

FULL ESTIMATED COST

0.21 0.21

FILE 'MEDLINE' ENTERED AT 17:28:27 ON 24 JUL 2003

FILE 'USPATFULL' ENTERED AT 17:28:27 ON 24 JUL 2003 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 17:28:27 ON 24 JUL 2003 COPYRIGHT (C) 2003 DERWENT INFORMATION LTD

FILE 'EMBASE' ENTERED AT 17:28:27 ON 24 JUL 2003 COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:28:27 ON 24 JUL 2003 COPYRIGHT 2003 THOMSON ISI

FILE 'FSTA' ENTERED AT 17:28:27 ON 24 JUL 2003 COPYRIGHT (C) 2003 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 17:28:27 ON 24 JUL 2003 COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'WPIDS' ENTERED AT 17:28:27 ON 24 JUL 2003 COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 17:28:27 ON 24 JUL 2003 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'HCAPLUS' ENTERED AT 17:28:27 ON 24 JUL 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s albumin fusion protein 2651 ALBUMIN FUSION PROTEIN T₁1

=> s albumin fusion protein () increased shelf-life 1 ALBUMIN FUSION PROTEIN (W) INCREASED SHELF-LIFE

=> d 12 ti abs ibib tot

L2 ANSWER 1 OF 1 USPATFULL on STN

TTAlbumin fusion proteins AB

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion

proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2003:181414 USPATFULL

TITLE:

Albumin fusion proteins

INVENTOR(S):

Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003125247	A1.	20030703	
APPLICATION INFO.:	US 2001-833041	A1	20010412	(9)

NUMBER DATE _____ PRIORITY INFORMATION: US 2000-256931P 20001221 (60) US 2000-199384P 20000425 (60) 20000412 (60) US 2000-229358P DOCUMENT TYPE: Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,

ROCKVILLE, MD, 20850

NUMBER OF CLAIMS:

29 1

EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

20 Drawing Page(s)

LINE COUNT:

15235

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

TI

AB

(FILE 'HOME' ENTERED AT 17:28:02 ON 24 JUL 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, SCISEARCH, FSTA, JICST-EPLUS, WPIDS, BIOSIS, HCAPLUS' ENTERED AT 17:28:27 ON 24 JUL 2003

2651 S ALBUMIN FUSION PROTEIN L1

1.2 1 S ALBUMIN FUSION PROTEIN () INCREASED SHELF-LIFE

=> s l1 and extended shelf-life

188 L1 AND EXTENDED SHELF-LIFE L_3

=> s l1 and increase half-life

1 L1 AND INCREASE HALF-LIFE L4

=> d l4 ti abs ibib tot

ANSWER 1 OF 1 USPATFULL on STN L4

Tumor necrosis factor receptors 6alpha & 6beta

The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6.alpha. & -6.beta. proteins. TNFR-6.alpha. & -6.beta. polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6.alpha. & -6.beta. activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2002:272468 USPATFULL TITLE:

Tumor necrosis factor receptors 6alpha & 6beta INVENTOR (S): Gentz, Reiner L., Rockville, MD, UNITED STATES Ebner, Reinhard, Gaithersburg, MD, UNITED STATES

Yu, Guo-Liang, Berkeley, CA, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES Ni, Jian, Germantown, MD, UNITED STATES Feng, Ping, Gaithersburg, MD, UNITED STATES

PATENT ASSIGNEE(S):

Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

NUMBER DATE

_______ US 2001-303224P 20010706 (60) PRIORITY INFORMATION: US 2000-252131P 20001121 (60) 20000825 (60) US 2000-227598P 19991201 (60) US 1999-168235P US 1999-146371P 19990802 (60) US 1999-131964P 19990430 (60) 19990427 (60) US 1999-131270P US 1999-124092P 19990312 (60) US 1999-121774P 19990304 (60) US 1997-35496P 19970114 (60)

DOCUMENT TYPE: FILE SEGMENT:

Utility APPLICATION

LEGAL REPRESENTATIVE:

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,

ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: EXEMPLARY CLAIM: 48 1

NUMBER OF DRAWINGS:

23 Drawing Page(s)

LINE COUNT: 12989

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> dhis

DHIS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> d his

L1

T.3

(FILE 'HOME' ENTERED AT 17:28:02 ON 24 JUL 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, SCISEARCH, FSTA, JICST-EPLUS, WPIDS, BIOSIS, HCAPLUS' ENTERED AT 17:28:27 ON 24 JUL 2003

2651 S ALBUMIN FUSION PROTEIN

L2 1 S ALBUMIN FUSION PROTEIN () INCREASED SHELF-LIFE

188 S L1 AND EXTENDED SHELF-LIFE

L4 1 S L1 AND INCREASE HALF-LIFE

=> s 13 and increase albumin activity

L5 0 L3 AND INCREASE ALBUMIN ACTIVITY

=> s 13 and non-glycosylation

L6 0 L3 AND NON-GLYCOSYLATION

=> s 13 and yeast cell

L7 1 L3 AND YEAST CELL

=> d l7 ti abs ibib tot

ANSWER 1 OF 1 USPATFULL on STN L7

Albumin fusion proteins TI

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Haseltine, William A., Washington, DC, UNITED STATES

20000412 (60)

NUMBER KIND DATE US 2003125247 PATENT INFORMATION: A1 20030703 APPLICATION INFO.: US 2001-833041 A1 20010412 (9)

> NUMBER DATE ______ 20001221 (60) US 2000-256931P US 2000-199384P 20000425 (60)

US 2000-229358P DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,

ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29 EXEMPLARY CLAIM: 1

PRIORITY INFORMATION:

NUMBER OF DRAWINGS: 20 Drawing Page(s)

LINE COUNT: 15235

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

L1

(FILE 'HOME' ENTERED AT 17:28:02 ON 24 JUL 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, SCISEARCH, FSTA, JICST-EPLUS, WPIDS, BIOSIS, HCAPLUS' ENTERED AT 17:28:27 ON 24 JUL 2003

2651 S ALBUMIN FUSION PROTEIN

1 S ALBUMIN FUSION PROTEIN () INCREASED SHELF-LIFE L2

L3 188 S L1 AND EXTENDED SHELF-LIFE 1 S L1 AND INCREASE HALF-LIFE T.4

 L_5 0 S L3 AND INCREASE ALBUMIN ACTIVITY

0 S L3 AND NON-GLYCOSYLATION L6

L71 S L3 AND YEAST CELL

=> s 13 and protease deficient

2 L3 AND PROTEASE DEFICIENT L₈

=> d l8 ti abs ibib tot

L8ANSWER 1 OF 2 USPATFULL on STN

Albumin fusion proteins

The present invention encompasses albumin fusion proteins. Nucleic acid AB molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2003:181414 USPATFULL

TITLE:

Albumin fusion proteins

INVENTOR(S):

Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003125247	A1	20030703	
APPLICATION INFO.:	US 2001-833041	A1	20010412	(9)

NUMBER DATE ______

PRIORITY INFORMATION:

US 2000-256931P 20001221 (60) 20000425 (60)

US 2000-199384P US 2000-229358P

20000412 (60)

DOCUMENT TYPE: FILE SEGMENT:

Utility APPLICATION

LEGAL REPRESENTATIVE:

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,

ROCKVILLE, MD, 20850

NUMBER OF CLAIMS:

29 1

EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

20 Drawing Page(s)

LINE COUNT:

15235

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

- ANSWER 2 OF 2 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN L8
- TI New albumin fusion proteins with extended shelf

life, useful for treating leukemia, warts, hepatitis, multiple sclerosis and AIDS, comprises therapeutic protein fused to albumin.

ΑN 2002-179329 [23] WPIDS

CR 2001-602931 [68]

AΒ WO 200179271 A UPAB: 20030211

NOVELTY - An albumin fusion protein (I)

comprising:

- (a) a therapeutic protein (X) and albumin (A) containing a fully defined sequence (S1) of 585 amino acids as given in the specification;
- (b) X and a fragment or variants of S1, where the fragment or variants has albumin activity; or
- (c) a fragment or variant of X and A, where the fragment or variant has a biological activity of X, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) an albumin fusion protein (II) comprising a peptide inserted into A comprising amino acids 54-61, 76-89, 92-100, 170-176, 247-252, 266-277, 280-288, 362-368, 439-447, 462-475, 478-486 or 560-566 of S1;
- (2) an albumin fusion protein (III) comprising a single chain antibody or its portion and A or its fragment or
- (3) a composition comprising any of (I)-(III) and a pharmaceutically active carrier;
 - (4) a kit comprising the composition;

(5) treating a disease or disorder that is modulated by X in a patient comprising administering any of (I)-(III);

(6) extending the shelf life of X comprising fusing X or its fragment or variant to A or its fragment or variant, sufficient to extend the shelf-life of X compared to the shelf life of X in an unfused state;

- (7) a nucleic acid molecule (IV) comprising a polynucleotide sequence encoding any of (I)-(III);
 - (8) a vector comprising (IV); and
 - (9) a host cell comprising (IV).

ACTIVITY - Cytostatic; dermatological; virucide; anti-HIV; neuroprotective; hepatotropic; antiinflammatory. Tests are described but no results are given in the source material.

MECHANISM OF ACTION - Gene therapy.

USE - The fusion protein is useful for the treatment of hairy cell leukemia, Kaposi's sarcoma, genital warts, anal warts, chronic hepatitis B, chronic non-A, non-B hepatitis, hepatitis C/D, chronic myelogenous leukemia, renal cell carcinoma, bladder carcinoma, ovarian carcinoma, cervical carcinoma, skin cancer, recurrent respirator papillomatosis, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, melanoma, multiple myeloma, acquired immunodeficiency syndrome (AIDS), multiple sclerosis and glioblastoma. The fusion of albumin extends the shelf life and the in vivo and in vitro biological activity of the therapeutic protein (all claimed).

ADVANTAGE - Therapeutic proteins can be stabilized to extend shelf life and/or retain the protein's activity for extended periods of time in solution, in vivo or in vitro by genetically or chemically fusing the protein to albumin or its fragment or variant. In addition the use of albumin fusion proteins reduces the need to formulate protein solutions with large excesses of carrier proteins to prevent loss of therapeutic protein due to factors such as binding to the container. The extension of shelf life was tested by measuring biological activity (Nb2 cell proliferation) of human albumin-human growth hormone (HA-hGH) fusion protein remaining after incubation in cell culture media for up to 3 weeks at 37 deg. C. At week 3 there was still approx. 95% cell proliferation compared to no activity of unfused hGH (no observed activity by week 2).

ACCESSION NUMBER:

2002-179329 [23] WPIDS

CROSS REFERENCE:

2001-602931 [68]

DOC. NO. CPI:

C2002-055553

TITLE:

New albumin fusion proteins with extended

shelf life, useful for treating

leukemia, warts, hepatitis, multiple sclerosis and AIDS,

comprises therapeutic protein fused to albumin.

DERWENT CLASS:

INVENTOR(S):

B04 D16

): BALLA

BALLANCE, D J; PRIOR, C P; SADEGHI, H; SLEEP, D; TURNER,

ΑJ

PATENT ASSIGNEE(S):

(DELZ) DELTA BIOTECHNOLOGY LTD; (PRIN-N) PRINCIPIA PHARM

CORP

COUNTRY COUNT:

96

PATENT INFORMATION:

PATENT NO KIND DATE WEEK LA PG

WO 2001079271 A1 20011025 (200223)* EN 294

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2001061024 A 20011030 (200225)

EP 1278767 A1 20030129 (200310) EN

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

APPLICATION DETAILS:

PATENT NO KIND APPLICA	TION DATE
AU 2001061024 A AU 2001 EP 1278767 A1 EP 2001	-US12009 20010412 -61024 20010412 -934875 20010412 -US12009 20010412

FILING DETAILS:

PAT	TENT NO K	CIND			PAT	ENT NO
ΑU	2001061024	. A	Based	on	WO	200179271
ΕP	1278767	A1	Based	on	WO	200179271

PRIORITY APPLN. INFO: US 2000-256931P 20001221; US 2000-229358P 20000412; US 2000-199384P 20000425

=> d his

(FILE 'HOME' ENTERED AT 17:28:02 ON 24 JUL 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, SCISEARCH, FSTA, JICST-EPLUS, WPIDS, BIOSIS, HCAPLUS' ENTERED AT 17:28:27 ON 24 JUL 2003
L1 2651 S ALBUMIN FUSION PROTEIN

L2 1 S ALBUMIN FUSION PROTEIN () INCREASED SHELF-LIFE
L3 188 S L1 AND EXTENDED SHELF-LIFE

L4 1 S L1 AND INCREASE HALF-LIFE

L5 0 S L3 AND INCREASE ALBUMIN ACTIVITY

L6 0 S L3 AND NON-GLYCOSYLATION

L7 1 S L3 AND YEAST CELL

L8 2 S L3 AND PROTEASE DEFICIENT

=> d his

L2

L5

AB

(FILE 'HOME' ENTERED AT 17:28:02 ON 24 JUL 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, SCISEARCH, FSTA, JICST-EPLUS, WPIDS, BIOSIS, HCAPLUS' ENTERED AT 17:28:27 ON 24 JUL 2003

L1 2651 S ALBUMIN FUSION PROTEIN

1 S ALBUMIN FUSION PROTEIN () INCREASED SHELF-LIFE

3 188 S L1 AND EXTENDED SHELF-LIFE

L4 1 S L1 AND INCREASE HALF-LIFE

0 S L3 AND INCREASE ALBUMIN ACTIVITY

L6 0 S L3 AND NON-GLYCOSYLATION

L7 1 S L3 AND YEAST CELL

L8 2 S L3 AND PROTEASE DEFICIENT

=> s 13 and kit

L9 2 L3 AND KIT

=> d 19 ti abs ibib tot

L9 ANSWER 1 OF 2 USPATFULL on STN

TI Albumin fusion proteins

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising

albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2003:181414 USPATFULL Albumin fusion proteins

INVENTOR(S):

TITLE:

Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003125247			
APPLICATION INFO.:	US 2001-833041	A1	20010412	(9)
	NUMBER	DA	TE	
PRIORITY INFORMATION:	US 2000-256931P	2000	1221 (60)	
	US 2000-199384P		` '	
DOCUMENT TYPE: FILE SEGMENT:	US 2000-229358P Utility APPLICATION	2000	0412 (60)	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIE ROCKVILLE, MD, 20		NC, 9410 K	EY WEST AVENUE,
NUMBER OF CLAIMS:	29			
EXEMPLARY CLAIM: NUMBER OF DRAWINGS: LINE COUNT:	1 20 Drawing Page(s 15235)		
CAS INDEXING IS AVAILAB		٠.		

- Ъ9 ANSWER 2 OF 2 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
- TT New albumin fusion proteins with extended shelf life, useful for treating leukemia, warts, hepatitis, multiple sclerosis and AIDS, comprises therapeutic protein fused to albumin.
- AN2002-179329 [23] WPIDS
- CR 2001-602931 [68]
- AΒ WO 200179271 A UPAB: 20030211

NOVELTY - An albumin fusion protein (I) comprising:

- (a) a therapeutic protein (X) and albumin (A) containing a fully defined sequence (S1) of 585 amino acids as given in the specification;
- (b) X and a fragment or variants of S1, where the fragment or variants has albumin activity; or
- (c) a fragment or variant of X and A, where the fragment or variant has a biological activity of X, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) an albumin fusion protein (II) comprising a peptide inserted into A comprising amino acids 54-61, 76-89, 92-100, 170-176, 247-252, 266-277, 280-288, 362-368, 439-447, 462-475, 478-486 or 560-566 of S1;
- (2) an albumin fusion protein (III) comprising a single chain antibody or its portion and A or its fragment or variant;
- (3) a composition comprising any of (I)-(III) and a pharmaceutically active carrier;
 - (4) a kit comprising the composition;
- (5) treating a disease or disorder that is modulated by X in a
- patient comprising administering any of (I)-(III);
 (6) extending the shelf life of X comprising fusing X or its fragment or variant to A or its fragment or variant, sufficient to extend the shelf-life of X compared to the shelf life of X in an unfused state;
- (7) a nucleic acid molecule (IV) comprising a polynucleotide sequence encoding any of (I)-(III);

(8) a vector comprising (IV); and

(9) a host cell comprising (IV).

ACTIVITY - Cytostatic; dermatological; virucide; anti-HIV; neuroprotective; hepatotropic; antiinflammatory. Tests are described but no results are given in the source material.

MECHANISM OF ACTION - Gene therapy.

USE - The fusion protein is useful for the treatment of hairy cell leukemia, Kaposi's sarcoma, genital warts, anal warts, chronic hepatitis B, chronic non-A, non-B hepatitis, hepatitis C/D, chronic myelogenous leukemia, renal cell carcinoma, bladder carcinoma, ovarian carcinoma, cervical carcinoma, skin cancer, recurrent respirator papillomatosis, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, melanoma, multiple myeloma, acquired immunodeficiency syndrome (AIDS), multiple sclerosis and glioblastoma. The fusion of albumin extends the shelf life and the in vivo and in vitro biological activity of the therapeutic protein (all claimed).

ADVANTAGE - Therapeutic proteins can be stabilized to extend shelf life and/or retain the protein's activity for extended periods of time in solution, in vivo or in vitro by genetically or chemically fusing the protein to albumin or its fragment or variant. In addition the use of albumin fusion proteins reduces the need to formulate protein solutions with large excesses of carrier proteins to prevent loss of therapeutic protein due to factors such as binding to the container. The extension of shelf life was tested by measuring biological activity (Nb2 cell proliferation) of human albumin-human growth hormone (HA-hGH) fusion protein remaining after incubation in cell culture media for up to 3 weeks at 37 deg. C. At week 3 there was still approx. 95% cell proliferation compared to no activity of unfused hGH (no observed activity by week 2). Dwg.0/18

ACCESSION NUMBER:

2002-179329 [23] WPIDS

CROSS REFERENCE:

2001-602931 [68]

DOC. NO. CPI:

C2002-055553

TITLE:

New albumin fusion proteins with extended

shelf life, useful for treating

leukemia, warts, hepatitis, multiple sclerosis and AIDS,

comprises therapeutic protein fused to albumin.

DERWENT CLASS:

B04 D16

INVENTOR (S):

BALLANCE, D J; PRIOR, C P; SADEGHI, H; SLEEP, D; TURNER,

ΑЈ

PATENT ASSIGNEE(S):

(DELZ) DELTA BIOTECHNOLOGY LTD; (PRIN-N) PRINCIPIA PHARM

CORP

COUNTRY COUNT:

96

PATENT INFORMATION:

PATENT NO KIND DATE WEEK LA PG

WO 2001079271 A1 20011025 (200223)* EN 294

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2001061024 A 20011030 (200225)

EP 1278767 A1 20030129 (200310) EN

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

APPLICATION DETAILS:

PATENT NO K	IND	API	PLICATION	DATE
WO 2001079271	A1	WO	2001-US12009	20010412
AU 2001061024	A	ΑU	2001-61024	20010412
EP 1278767	A1	EΡ	2001-934875	20010412

WO 2001-US12009 20010412

FILING DETAILS:

DOCUMENT TYPE:

```
PATENT NO KIND
                                       PATENT NO
     AU 2001061024 A Based on
                                       WO 200179271
     EP 1278767
                 Al Based on
                                       WO 200179271
PRIORITY APPLN. INFO: US 2000-256931P 20001221; US 2000-229358P
                      20000412; US 2000-199384P 20000425
=> e rosen, c/au
E1
                   ROSEN ZVI M/AU
             7
E2
             7
                   ROSEN ZVI MICHAL/AU
E3
             0 --> ROSEN, C/AU
                 ROSENA BRUCE R/AU
E4
             1.
E5
                  ROSENABUM S/AU
             1
E6
             1
                  ROSENACKER A F/AU
E7
                   ROSENACKER ARTHUR F/AU
             1
E8
             4
                  ROSENADA CEPERO R/AU
                 ROSENAGER L/AU
E9
            1
E10
            2
                 ROSENAK B/AU
            71
                 ROSENAK B D/AU
E11
E12
            9
                   ROSENAK BERNARD D/AU
=> e haseltine, W/au
                   HASELTINE WILLIAM G/AU
E1
            1
                   HASELTINE WILLIAM GAGE/AU
E2
             1
E3
             0 --> HASELTINE, W/AU
                  HASELTLINE F P/AU
E4
            1
E5
            8
                  HASELTON A/AU
E6
            5
                  HASELTON AARON/AU
                  HASELTON B J/AU
E7
            1
            4
                  HASELTON C/AU
E8
E9
             1
                  HASELTON C B/AU
E10
             9
                   HASELTON C J/AU
                   HASELTON C L/AU
            37
E11
                  HASELTON CAROLE J/AU
E12
            5
=> s e1
L10
             1 "HASELTINE WILLIAM G"/AU
=> s e2
             1 "HASELTINE WILLIAM GAGE"/AU
=> d l10 ti abs ibib tot
    ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS on STN
TI
     Physicochemical properties of mono- and diisocyanates
AR
     Liq. d., viscosity, sp. heat, and vapor pressure data are reported for a
     new class of mono- and diisocyanates.
ACCESSION NUMBER:
                         1986:540063 HCAPLUS
DOCUMENT NUMBER:
                         105:140063
TITLE:
                         Physicochemical properties of mono- and diisocyanates
AUTHOR(S):
                         Achorn, Peter J.; Haseltine, William G.;
                         Miller, J. K.
CORPORATE SOURCE:
                         Chem. Res. Div., Am. Cyanamid Co., Stamford, CT,
                         06904-0060, USA
SOURCE:
                         Journal of Chemical and Engineering Data (1986),
                         31(4), 385-7
```

CODEN: JCEAAX; ISSN: 0021-9568

Journal

LANGUAGE:

English

=> d l11 ti abs ibib tot

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS on STN TI High pressure carbon-13 nuclear magnetic resonance relaxation study of

2-n-buty1-3-n-hexylnaphthalene

Unavailable

ACCESSION NUMBER:

1981:559261 HCAPLUS 95:159261

DOCUMENT NUMBER: TITLE:

High pressure carbon-13 nuclear magnetic resonance

relaxation study of 2-n-butyl-3-n-hexylnaphthalene

AUTHOR(S): Haseltine, William Gage

CORPORATE SOURCE:

SOURCE:

Pennsylvania State Univ., University Park, PA, USA (1981) 195 pp. Avail.: Univ. Microfilms Int., Order

No. 8112809


From: Diss. Abstr. Int. B 1981, 42(1), 230

DOCUMENT TYPE:

LANGUAGE:


Dissertation

English




Search Results -

Terms	Documents
16 and L9	119



Search:



Search History

DATE: Thursday, July 24, 2003 Printable Copy Create Case

Set Name Query		Hit Count	
side by side			result set
DB=US	PT; PLUR=YES; OP=OR		
<u>L10</u>	16 and L9	119	<u>L10</u>
<u>L9</u>	non-glycosylated and L8	1006	<u>L9</u>
<u>L8</u>	protease deficient and 16	30313	<u>L8</u>
<u>L7</u>	stable solution and L6	471777	<u>L7</u>
<u>L6</u>	storage and L5	3272	<u>L6</u>
<u>L5</u>	L3 and stability	6708	<u>L5</u>
<u>L4</u>	in vivo activity and L3	2927400	<u>L4</u>
<u>L3</u>	yeast and L2	11983	<u>L3</u>
<u>L2</u>	extended shelf-life and L1	538751	<u>L2</u>
<u>L1</u>	fusion albumin protein	189881	<u>L1</u>

END OF SEARCH HISTORY

ZIP CODE

WEST

Generate Collection

Print

Search Results - Record(s) 1 through 10 of 119 returned.

☐ 1. Document ID: US 6593112 B1

L10: Entry 1 of 119

File: USPT

Jul 15, 2003

COUNTRY

US-PAT-NO: 6593112

DOCUMENT-IDENTIFIER: US 6593112 B1

TITLE: Polynucleotides encoding fibroblast growth factor 15

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME C.

Greene; John M. Gaithersburg

Rosen; Craig A. Laytonsv Alderson; Ralph Gaithers

Melder; Robert J.

Duan; D. Roxanne

CITY

Laytonsville

e

Gaithersburg Gaithersburg

Bethesda

MD MD

MD

MD

STATE

US-CL-CURRENT: $\frac{435}{69.4}$; $\frac{435}{243}$, $\frac{435}{320.1}$, $\frac{435}{325}$, $\frac{435}{69.7}$, $\frac{514}{44}$, $\frac{530}{300}$, $\frac{530}{399}$, $\frac{536}{23.1}$, $\frac{536}{23.5}$

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachiments | Claims | MiliC | Drawi Desc | Image

2. Document ID: US 6592865 B2

L10: Entry 2 of 119

File: USPT

Jul 15, 2003

US-PAT-NO: 6592865

DOCUMENT-IDENTIFIER: US 6592865 B2

TITLE: Methods and compositions for modulating ACE-2 activity

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Parry; Tom J.

Walkersville

MD

Sekut; Les

Ijamsville

MD

US-CL-CURRENT: 514/15, 514/2

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMMC | Draw Desc | Image

3. Document ID: US 6566325 B2

L10: Entry 3 of 119

File: USPT

May 20, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Mason; Hugh S. Ithaca NY
Thanavala; Yasmin Williamsville NY
Arntzen; Charles Joel Ithaca NY
Richter; Elizabeth Ithaca NY

US-CL-CURRENT: 435/320.1; 435/69.3, 435/71.2, 536/23.4

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMC Draw Desc Image

8. Document ID: US 6544761 B2

L10: Entry 8 of 119 File: USPT Apr 8, 2003

US-PAT-NO: 6544761

DOCUMENT-IDENTIFIER: US 6544761 B2

TITLE: Human tissue inhibitor of metalloproteinase-4

DATE-ISSUED: April 8, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Greene; John M. Gaithersburg MD Rosen; Craig A. Laytonsville MD

US-CL-CURRENT: 435/69.2; 514/12, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KMC | Draw Desc | Image |

9. Document ID: US 6544505 B2

L10: Entry 9 of 119 File: USPT Apr 8, 2003

US-PAT-NO: 6544505

DOCUMENT-IDENTIFIER: US 6544505 B2

TITLE: Interferon-epsilon

DATE-ISSUED: April 8, 2003

 ${\tt INVENTOR-INFORMATION:}$

NAME CITY STATE ZIP CODE COUNTRY

Conklin; Darrell C. Seattle WA
Grant; Francis J. Seattle WA
Rixon; Mark W. Issaquah WA
Kindsvogel; Wayne Seattle WA

US-CL-CURRENT: 424/85.4; 424/185.1, 435/69.51, 530/350, 530/351

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Millio | Draw Desc | Image

10. Document ID: US 6541623 B1

L10: Entry 10 of 119

File: USPT

Apr 1, 2003

US-PAT-NO: 6541623

DOCUMENT-IDENTIFIER: US 6541623 B1

TITLE: Interleukin--1 receptor antagonist and uses thereof

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

Ho; Alice Suk-Yue

NAME

CITY

STATE 2

ZIP CODE

COUNTRY

Ford; John

San Mateo

CA

Union City CA

Pace; Ann

Scotts Valley

CA

US-CL-CURRENT: $\underline{536/24.3}$; $\underline{435/287.2}$, $\underline{435/288.3}$, $\underline{435/288.4}$, $\underline{536/23.1}$

Full Title Citati	on Front Review Classifi	cation Date Referen	se Sequences	Attachments	1000C Draw Deso Image	
Con A constraint and the control of		Generate Co	lection	Print		
Company of the Compan	Terms			Docun	nents	
l6 and	L9				119	

Display Format: CIT Change Format

Previous Page

Next Page

WEST

Generate Collection

Print

MD

MD

Search Results - Record(s) 21 through 30 of 119 returned.

☐ 21. Document ID: US 6495128 B1

L10: Entry 21 of 119

File: USPT

Dec 17, 2002

US-PAT-NO: 6495128

DOCUMENT-IDENTIFIER: US 6495128 B1

TITLE: Human chemokine .beta.-7 deletion and substitution proteins

DATE-ISSUED: December 17, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Salcedo; Theodora W.

Gaithersburg

COONIKI

Patel; Vikram P.

Germantown

Nibbs; Robert John Benjamin

Glasgow

GB

Graham; Gerard John

Glasgow

GB

US-CL-CURRENT: $\frac{424}{85.1}$; $\frac{435}{254.11}$, $\frac{435}{254.3}$, $\frac{435}{320.1}$, $\frac{435}{325}$, $\frac{435}{435}$, $\frac{435}{69.5}$, $\frac{435}{69.7}$, $\frac{435}{71.1}$, $\frac{435}{71.2}$, $\frac{530}{324}$, $\frac{536}{23.5}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

22. Document ID: US 6482612 B1

L10: Entry 22 of 119

File: USPT

Nov 19, 2002

US-PAT-NO: 6482612

DOCUMENT-IDENTIFIER: US 6482612 B1

TITLE: Adipocyte-specific protein homologs

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Sheppard; Paul O.

Redmond

WA

Humes; Jacqueline M.

Seattle

WA

US-CL-CURRENT: $\frac{435}{69.1}$; $\frac{435}{252.3}$, $\frac{435}{320.1}$, $\frac{435}{6}$, $\frac{435}{7.2}$, $\frac{435}{7.21}$, $\frac{436}{501}$, $\frac{514}{2}$, $\frac{530}{350}$, $\frac{536}{23.5}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments

10MC Draw Desc Image

23. Document ID: US 6476209 B1

L10: Entry 23 of 119

File: USPT

Nov 5, 2002

US-PAT-NO: 6476209

DOCUMENT-IDENTIFIER: US 6476209 B1

TITLE: Polynucleotides, materials incorporating them, and methods for using them

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Glenn; Matthew Auckland NZ Lubbers; Mark W. Palmerston North NZ

Dekker; James Palmerston North NZ

US-CL-CURRENT: $\underline{536}/\underline{23.1}$; $\underline{435}/\underline{6}$, $\underline{435}/\underline{91.1}$, $\underline{530}/\underline{200}$, $\underline{536}/\underline{22.1}$

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments |

10MC | Draw Desc | Image

24. Document ID: US 6476195 B1

L10: Entry 24 of 119 File: USPT Nov 5, 2002

US-PAT-NO: 6476195

DOCUMENT-IDENTIFIER: US 6476195 B1

TITLE: Secreted protein HNFGF20

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

ZIP CODE COUNTRY CITY STATE NAME Silver Spring MD Komatsoulis; George Laytonsville MD Rosen; Craig A. Ruben; Steven M. Olney MD Bethesda MD Duan; Roxanne D. Moore; Paul A. Germantown MD Gaithersburg MDShi; Yanggu LaFleur; David W. Washington DC CA Wei; Ying-Fei Berkeley Rockville MD Ni; Jian Florence; Kimberly A. Rockville MD Young; Paul Gaithersburg MD Brewer; Laurie A. St. Paul MN Soppet; Daniel R. Centreville VA Endress; Gregory A. Potomac MD Ebner; Reinhard Gaithersburg Gaithersburg Olsen; Henrik MD Cincinnati OH Mucenski; Michael

US-CL-CURRENT: 530/350; 435/6, 435/7.1, 536/23.1

Full Title Citation Front Review Classification Date Reference Sequences Attachments NMC Draw Desc Image